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Grace et al.’s analysis, the profile of
LKD relationships and the reduced
chance of receiving an LKD transplant
associated with socioeconomic status
remained constant between states and
across time despite marked differences
between states and increases over time
in absolute LKD rates. Perhaps one
reason for this is the relatively low
percentage of patients in Australia who
are activated on the transplant waiting
list compared with other countries—
18% of dialysis patients younger than
65 in Australia compared with 49% in
France, 48% in the United Kingdom,
and 33% in the United States.8
There are also some noteworthy high-
achieving transplant program models
around the world. In Norway, a very
active LKD program makes it possible for
nearly 90% of patients younger than 65
on dialysis to access the deceased donor
transplant waiting list, and almost all of
these receive a transplant within 4 years
of starting dialysis.6 Iran has also achieved
remarkable transplant access through
LKD transplantation, in this case with a
government initiative regulating and
financially supporting living unrelated
donation.9 Although such an approach
is not without controversy, its effect has
been to develop skills in a generation of
surgeons and enable the setting up of a
very promising deceased donor scheme.9
Although medical factors will always
play a role, the importance of psycho-
logical, social, and cultural factors in
determining differences in rates of trans-
plantation is increasingly being recog-
nized,10 particularly through the patient’s
interpretation and assessment of risk
associated with transplantation and how
it compares with the status quo of
dialysis.1 It has even been suggested that
socioeconomic status no longer associates
with reduced access once differences in
health, functional status, and psycho-
social factors such as ‘attitudes toward
treatment’ have been accounted for.11 If
we are to reduce inequity in access to
transplantation, we must first understand
the educational, psychological, and social
milieu of specific patients at specific
times. Some of these factors may have
more potential for modification than the
patient demographics and comorbidity.
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The OSCAR for cardiovascular
disease prevention in chronic
kidney disease goes to blood
pressure control
Alexandros Briasoulis1 and George L. Bakris1
Nephropathy progression is slowed and cardiovascular events reduced
in patients with stage 3 or higher chronic kidney disease when blood
pressure is controlled using combinations of renin–angiotensin system
(RAS) blockers with dihydropyridine calcium channel blockers or diuretics.
We discuss a trial comparing high-dose RAS blockade with lower-dose
RAS blockade combined with a dihydropyridine calcium channel blocker.
The primary outcome was cardiovascular events. The combination
group had better blood pressure control and fewer total events.
Kidney International (2012) 83, 20–22. doi:10.1038/ki.2012.364
Cardiovascular disease is the leading cause
of mortality in patients with chronic
kidney disease (CKD), stage 3 or high-
er; their risk increases as estimated
glomerular filtration rate (eGFR) falls.
Recently, stage 3 or higher CKD was
acknowledged as contributing more
risk for all-cause mortality than prior
myocardial infarction or diabetes.1
Almost all people with CKD, stage 3
or higher, require two or more medi-
cations to help achieve guideline
recommended blood pressure goals.2
Before the completion of the Avoiding
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Cardiovascular Events through Combi-
nation Therapy in Patients Living with
Systolic Hypertension (ACCOMPLISH)
trial, no cardiovascular outcome trial
ever initiated single-pill combination
(SPC) therapy for blood pressure
control.3 The rationale for an SPC anti-
hypertensive treatment was centered on
several animal studies demonstrating
improved vascular function and nitric
oxide release when either the renin–
angiotensin system (RAS) blocker
benazepril or the dihydropyridine cal-
cium channel blocker amlodipine was
given alone, with an additive effect
when combined.4,5 This was not seen
when thiazide diuretics were given.6
The ACCOMPLISH trial was a
randomized, double-blind study invol-
ving older hypertensive patients (mean
age 68 years) with a history of ischemic
heart disease, peripheral vascular dis-
ease, stroke, or diabetes that examined
the effects on cardiovascular outcomes
of treatment with benazepril combined
with amlodipine or hydrochlorothia-
zide.3 The 2% absolute risk reduction
in cardiovascular events seen in the
RAS blocker/amlodipine SPC group in
the main trial, as well as slowed
progression of CKD in those with an
eGFR less than 60ml/min per 1.73m2,
supports the concept of a blood
pressure-independent effect; there was
a 1.6-mmHg difference between groups
in systolic blood pressure on 24-h
ambulatory blood pressure monitor-
ing, favoring the diuretic.2,3,7
The additive effect of a RAS/calcium
channel blocker combination on
cardiovascular events in CKD was
evaluated by Kim-Mitsuyama et al.8
(this issue) in the OlmeSartan and
Calcium Antagonists Randomized
(OSCAR) trial. The trial compared
the effect of an angiotensin receptor
blocker with a calcium channel blocker
versus high-dose angiotensin receptor
blocker therapy on cardiovascular
morbidity and mortality in elderly
(mean age 74 years) Japanese people
with and without CKD. CKD was
defined as an eGFR less than 60ml/
min per 1.73m2.
Of 1078 patients in this open-label
trial, the authors randomized the 353
patients with CKD (32.7%) to 40mg
olmesartan (n¼ 181) or 20mg olme-
sartan with amlodipine or azelnidipine
added (n¼ 172). The primary end
point was broad and included cardio-
vascular end points and deterioration
of kidney function (doubling of serum
creatinine or dialysis), as well as non-
cardiovascular death. After 3 years of
follow-up, the authors concluded,
firstly, that blood pressure control was
more successful with combination
treatment; the mean difference in
systolic blood pressure between groups
was 3.7mmHg, and 17% more patients
achieved a blood pressure less than 140/
90mmHg in the combination group.
This finding is already well established
in other studies.9 Secondly, the
incidence of cardiovascular deaths and
illnesses as well as worsening CKD was
lower in the combination group, but
this difference was mainly driven by
fewer strokes (13 versus 5) and heart
failures (8 versus 1). There were no
differences in other end points, includ-
ing CKD progression, as treatment with
the angiotensin receptor blocker/
calcium channel blocker combination
failed to prevent reduction in eGFR
compared with high-dose olmesartan.
Lastly, the authors concluded that both
treatments have similar safety and
tolerability profiles and that the
higher the blood pressure, the greater
the likelihood of events.
This trial provides important infor-
mation but has many limitations,
including that it was open label and
was conducted in a homogenous co-
hort. Consequently, ethnic differences
cannot be evaluated; thus, these results
may not be generalizable to a broader
population. A meta-analysis of
open-label randomized trials without
blinding demonstrates that lack of
double blinding is associated with a
12% overestimation of intervention
benefits.10 Additionally, small sample
sizes in studies of interventions with
moderate effects have a substantial risk
of yielding false-positive or -negative
conclusions.
The OSCAR study was not designed
to examine the effects of the combina-
tion treatment on CKD progression or
24-hour blood pressure control, or the
impact of CKD progression on the
primary end point. Thus, it is under-
powered for any understanding of CKD
progression, as the trial is heavily
dependent on cardiovascular events.
Moreover, it confirms what is already
known about elderly patients with stage
3 CKD: that reducing blood pressure to
levels below 140/90mmHg is asso-
ciated with significantly reduced risk
of heart failure and stroke.11 Lastly,
CKD is appreciated as an independent
risk factor for cardiovascular death;
thus, this paper does not extend our
knowledge about the interaction of
diabetes with CKD.1 Taken together
with previous meta-analyses and recent
guidelines, OSCAR provides support for
the concept that an angiotensin receptor
blocker with a calcium antagonist is
effective in further reducing cardio-
vascular events in elderly patients with
CKD through better blood pressure
control. It does not extend our knowl-
edge, however, as to the slowing of CKD
progression or provide insights into new
approaches to optimally minimizing the
risk of CKD progression in elderly
patients with CKD. Moreover, it does
not provide information on the use
of single-pill combinations to achieve
blood pressure goals compared with
addition of a second agent.
On the basis of the available data,
antihypertensive treatment using SPCs
of RAS blockers with dihydropyridine
calcium channel blockers yields fewer
cardiovascular events and slows CKD
progression better in elderly patients
than RAS blocker/diuretic SPCs. More-
over, RAS blocker/calcium channel
blocker SPCs are better tolerated with
better adherence. The OSCAR trial
further supports these findings and
further supports combination rather
than monotherapy in such patients.
Future trials need to build on existing
knowledge and provide CKD outcomes
in elderly patients, as they are the
largest growing segment of people start-
ing dialysis in the Western world. In
conclusion, the OSCAR goes to achieve-
ment of the blood pressure goal of
o140/90mmHg using combination
therapy.
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